Cargando…
Intranasal esketamine use in bipolar disorder: A case report
Over the past few years, intranasal esketamine has been FDA-approved for treatment-resistant depression as well as MDD with suicidal ideation. In the clinical trials leading to the recent FDA approvals, subjects with a diagnosis of bipolar disorder were excluded from participation in the trial. The...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
College of Psychiatric & Neurologic Pharmacists
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287870/ https://www.ncbi.nlm.nih.gov/pubmed/34316423 http://dx.doi.org/10.9740/mhc.2021.07.259 |